Jubilant Life inks non-exclusive licensing pact with Gilead for Remdesivir

The drug, which is an injectable, got emergency approval from the US drug regulator recently.

Jubilant Life Sciences on Tuesday said it entered into a non-exclusive licensing agreement with US-based Gilead Sciences to make and sell the latter’s anti-viral drug Remdesivir in 127 countries, including India. The re-purposed Ebola drug is being considered as a potential therapy for coronavirus (Covid-19).
 

Most of these 127 countries are low-income and lower-middle income nations along with some upper-middle and high-income countries that face significant obstacles to healthcare access.
 

Under terms of the licensing agreement, Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process and can scale up production. This would, however, be